Company intelligence / Profile preview

RhoVac AB

Ownership: Private
Employees: ~2
Development stage: Phase 2

Overview

The company’s lead drug candidate RV001 has completed clinical phase I/II and entered clinical phase IIb development. It aims to stimulate the immune system to identify and destroy cells that over-express a certain protein linked to cancer progression. The approach involves peptide-based immunotherapy designed as a therapeutic cancer vaccine with potential effects on metastasis prevention or limitation[1][2][5].

Therapeutic areas: Oncology
Modalities: Peptide-based therapeutic cancer vaccine (immunotherapy)
Industry: Biotech

Drug pipeline

1 asset

RV001

Phase 2

Indications: prostate cancer, metastatic cancer

Beyond the preview

Go deeper on RhoVac AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RhoVac AB.

Explore the full profile